Tom Eirik Mollnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tom Eirik Mollnes has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Arnt E. Fiane
Department of Thoracic and Cardiovascular Surgery, Oslo University Hospital, Rikshospitalet, University of Oslo, Oslo, Norway
3 shared publications - Pål Aukrust
Faculty of Medicine, University of Oslo, 0318 Oslo, Norway
3 shared publications - Thor Ueland
Institute of Clinical Medicine, University of Oslo, Oslo, Norway
3 shared publications - Grethe Bergseth
Research Laboratory, Nordland Hospital, Bodø, Norway
2 shared publications - Guttorm Haraldsen
Institute of Clinical Medicine University of Oslo Oslo Norway
2 shared publications - John D. Lambris
University of Pennsylvania
2 shared publications
Latest Publications
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89, 125-126
Systemic- and local complement activation controls the NLRP3 inflammasome pathway in patients with atherosclerosis
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89, 125-126
Systemic- and local complement activation controls the NLRP3 inflammasome pathway in patients with atherosclerosis
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89
Neoepitope based assays to detect C5a – Pitfalls and interpretations
- 1 September 2017
- Published by Elsevier in Molecular Immunology
- Vol. 89
Neoepitope based assays to detect C5a – Pitfalls and interpretations
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e50
Alteration of circulatory cytokine levels in alcohol-use disorder patients with or without comorbid major depression
- 1 January 2015
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 146, e50
Alteration of circulatory cytokine levels in alcohol-use disorder patients with or without comorbid major depression
- Open Access
- 12 October 2009
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 10 (1) , 76-80
Perfusion temperature, thyroid hormones and inflammation during pediatric cardiac surgery
Objectives: During cardiopulmonary bypass (CPB) surgery there are several alterations in concentrations of thyroid hormones. Although hypothermia and inflammation have been implicated in the disturbed thyroid axis during CPB, these issues are far from clear. Methods and results: We measured serum/plasma concentrations of thyroid hormones and inflammatory mediators in children with body weight n=15, 32 °C) or moderate (n=15, 25 °C) hypothermia. During CPB there was a marked decrease in triiodothyronine (T3), free thyroxin (FT4) and thyroid-stimulating hormone (TSH), followed by a slight increase after 24 h, but without normalization 48 h after CPB. There was no difference in the thyroid response between the two hypothermia groups. During CPB the maximal changes in plasma levels of interleukin (IL)-6 and the chemokines, regulated on activation normal T cell expressed and secreted (RANTES) and monocyte chemoattractant protein (MCP)-1 were inversely correlated with the maximal changes in serum levels of T3. Conclusion: Our findings in this randomized trial do not support a role for hypothermia as a major cause of altered thyroxin responses in children undergoing CPB. Our finding may also suggest that in addition to IL-6, other inflammatory cytokines, such as chemokines, should be further investigated for their possible influence on the thyroid axis during CPB.
- 12 October 2009
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 10 (1) , 76-80
Open AccessPerfusion temperature, thyroid hormones and inflammation during pediatric cardiac surgery
Objectives: During cardiopulmonary bypass (CPB) surgery there are several alterations in concentrations of thyroid hormones. Although hypothermia and inflammation have been implicated in the disturbed thyroid axis during CPB, these issues are far from clear. Methods and results: We measured serum/plasma concentrations of thyroid hormones and inflammatory mediators in children with body weight n=15, 32 °C) or moderate (n=15, 25 °C) hypothermia. During CPB there was a marked decrease in triiodothyronine (T3), free thyroxin (FT4) and thyroid-stimulating hormone (TSH), followed by a slight increase after 24 h, but without normalization 48 h after CPB. There was no difference in the thyroid response between the two hypothermia groups. During CPB the maximal changes in plasma levels of interleukin (IL)-6 and the chemokines, regulated on activation normal T cell expressed and secreted (RANTES) and monocyte chemoattractant protein (MCP)-1 were inversely correlated with the maximal changes in serum levels of T3. Conclusion: Our findings in this randomized trial do not support a role for hypothermia as a major cause of altered thyroxin responses in children undergoing CPB. Our finding may also suggest that in addition to IL-6, other inflammatory cytokines, such as chemokines, should be further investigated for their possible influence on the thyroid axis during CPB.
- 1 January 2006
- Published by Elsevier in Molecular Immunology
- Vol. 43 (1-2) , 107-121
Strategies of therapeutic complement inhibition
- 1 January 2006
- Published by Elsevier in Molecular Immunology
- Vol. 43 (1-2) , 107-121
Strategies of therapeutic complement inhibition
- Open Access
- 8 April 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 26 (16) , 1660-1665
Low mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
Aims Transplant-associated coronary artery disease (TxCAD) is a major cause of post-transplant graft failure. The aim of this study was to investigate a possible role of mannose-binding lectin (MBL) deficiency and complement activation in TxCAD. Methods and results In a prospective study of heart transplant recipients (n=38) with a follow-up of 5.3±1.3 years (range: 0.9–6.6), angiographically verified TxCAD (n=6) was correlated to plasma MBL, complement activation, and endothelial activation (soluble E-selectin). MBL deficiency (P=0.020). Furthermore, one or more acute rejection episodes were observed in 6/6 of the MBL-deficient patients and in 15/32 of the MBL-sufficient patients (χ2; P=0.016). Complement activation (C4bc) correlated with soluble E-selectin (r=0.36; P=0.027), both being significantly higher in patients with ischaemia detected in the first biopsy (C4bc: 13.4±6.1 AU/mL; E-selectin: 96±13 ng/mL) than in those without ischaemia (C4bc: 6.3±0.5; E-selectin: 51±6; P=0.037 and 0.002). Finally, terminal complement complex correlated closely with mortality (P=0.002). Conclusion Low MBL was related to the development of TxCAD and acute rejection and increased complement activation correlated to histopathologic ischaemia and mortality after heart transplantation.
- 8 April 2005
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 26 (16) , 1660-1665
Open AccessLow mannose-binding lectin and increased complement activation correlate to allograft vasculopathy, ischaemia, and rejection after human heart transplantation
Aims Transplant-associated coronary artery disease (TxCAD) is a major cause of post-transplant graft failure. The aim of this study was to investigate a possible role of mannose-binding lectin (MBL) deficiency and complement activation in TxCAD. Methods and results In a prospective study of heart transplant recipients (n=38) with a follow-up of 5.3±1.3 years (range: 0.9–6.6), angiographically verified TxCAD (n=6) was correlated to plasma MBL, complement activation, and endothelial activation (soluble E-selectin). MBL deficiency (P=0.020). Furthermore, one or more acute rejection episodes were observed in 6/6 of the MBL-deficient patients and in 15/32 of the MBL-sufficient patients (χ2; P=0.016). Complement activation (C4bc) correlated with soluble E-selectin (r=0.36; P=0.027), both being significantly higher in patients with ischaemia detected in the first biopsy (C4bc: 13.4±6.1 AU/mL; E-selectin: 96±13 ng/mL) than in those without ischaemia (C4bc: 6.3±0.5; E-selectin: 51±6; P=0.037 and 0.002). Finally, terminal complement complex correlated closely with mortality (P=0.002). Conclusion Low MBL was related to the development of TxCAD and acute rejection and increased complement activation correlated to histopathologic ischaemia and mortality after heart transplantation.
- 28 October 2004
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 138 (3) , 439-446
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation
SUMMARY: Complement activation with formation of biologically potent mediators like C5a and the terminal C5b-9 complex (TCC) contributes essentially to development of inflammation and tissue damage in a number of autoimmune and inflammatory conditions. A particular role for complement in the ischaemia/reperfusion injury of the heart, skeletal muscle, central nervous system, intestine and kidney has been suggested from animal studies. Previous experiments in C3 and C4 knockout mice suggested an important role of the classical or lectin pathway in initiation of complement activation during intestinal ischaemia/reperfusion injury while later use of factor D knockout mice showed the alternative pathway to be critically involved. We hypothesized that alternative pathway amplification might play a more critical role in classical pathway-induced C5 activation than previously recognized and used pathway-selective inhibitory mAbs to further elucidate the role of the alternative pathway. Here we demonstrate that selective blockade of the alternative pathway by neutralizing factor D in human serum diluted 1 : 2 with mAb 166–32 inhibited more than 80% of C5a and TCC formation induced by solid phase IgM and solid- and fluid-phase human aggregated IgG via the classical pathway. The findings emphasize the influence of alternative pathway amplification on the effect of initial classical pathway activation and the therapeutic potential of inhibiting the alternative pathway in clinical conditions with excessive and uncontrolled complement activation.
- 28 October 2004
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 138 (3) , 439-446
The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation
SUMMARY: Complement activation with formation of biologically potent mediators like C5a and the terminal C5b-9 complex (TCC) contributes essentially to development of inflammation and tissue damage in a number of autoimmune and inflammatory conditions. A particular role for complement in the ischaemia/reperfusion injury of the heart, skeletal muscle, central nervous system, intestine and kidney has been suggested from animal studies. Previous experiments in C3 and C4 knockout mice suggested an important role of the classical or lectin pathway in initiation of complement activation during intestinal ischaemia/reperfusion injury while later use of factor D knockout mice showed the alternative pathway to be critically involved. We hypothesized that alternative pathway amplification might play a more critical role in classical pathway-induced C5 activation than previously recognized and used pathway-selective inhibitory mAbs to further elucidate the role of the alternative pathway. Here we demonstrate that selective blockade of the alternative pathway by neutralizing factor D in human serum diluted 1 : 2 with mAb 166–32 inhibited more than 80% of C5a and TCC formation induced by solid phase IgM and solid- and fluid-phase human aggregated IgG via the classical pathway. The findings emphasize the influence of alternative pathway amplification on the effect of initial classical pathway activation and the therapeutic potential of inhibiting the alternative pathway in clinical conditions with excessive and uncontrolled complement activation.
- 1 September 2003
- Published by Elsevier in Molecular Immunology
- Vol. 40 (2-4) , 135-143
Perspectives on complement in xenotransplantation
- 1 September 2003
- Published by Elsevier in Molecular Immunology
- Vol. 40 (2-4) , 135-143
Perspectives on complement in xenotransplantation
- 1 October 2002
- Published by Elsevier in Trends in Immunology
- Vol. 23 (10) , 475
C5a in sepsis – a novel link between complement and coagulation
- 1 October 2002
- Published by Elsevier in Trends in Immunology
- Vol. 23 (10) , 475
C5a in sepsis – a novel link between complement and coagulation
- 1 September 2002
- Vol. 100 (5) , 1869-77
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.
Complement plays an essential role in inflammation and tissue damage. However, it is largely unknown to what extent the system acts as a primary inducer of secondary mediator systems in the inflammatory network of human whole blood. Here we describe a novel in vitro model using the thrombin-specific hirudin analog lepirudin as anticoagulant, which, in contrast to heparin, did not interfere with complement activation. The model was used to study the role of complement in Escherichia coli-induced inflammatory responses. Granulocyte and monocyte oxidative burst was complement dependent as it was reduced by 85% and 70%, respectively, by the C3 [corrected] binding peptide compstatin. A similar reduction was found by inhibition of C5, C5a, and C5a receptor (C5aR). Furthermore, anti-CR3 antibodies were as efficient as the C5aR antagonist in reducing granulocyte oxidative burst, whereas blocking CD14 or C3aR had no effect. Up-regulation of granulocyte CR3 was virtually abolished by a C5aR antagonist. Opsonization and phagocytosis was completely inhibited by blocking of C5aR or CR3, whereas blocking of the FcgammaRs (CD16, CD32, CD64) had no effect. In contrast to oxidative burst and phagocytosis, cytokine secretion was largely complement independent. Thus, anti-CD14 abolished tumor necrosis factor-alpha, interleukin-6 (IL-6), and IL-10 secretion, whereas IL-8 was equally inhibited by anti-CD14 and compstatin. In conclusion, the present model is particularly useful for studying complement as part of the inflammatory network. The results emphasize a crucial role for C5a-C5aR interaction in E coli-induced up-regulation of CR3 and the subsequent oxidative burst and phagocytosis. Complement inhibition may have therapeutic implications in oxidative burst-induced tissue damage.
- 1 September 2002
- Vol. 100 (5) , 1869-77
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.
Complement plays an essential role in inflammation and tissue damage. However, it is largely unknown to what extent the system acts as a primary inducer of secondary mediator systems in the inflammatory network of human whole blood. Here we describe a novel in vitro model using the thrombin-specific hirudin analog lepirudin as anticoagulant, which, in contrast to heparin, did not interfere with complement activation. The model was used to study the role of complement in Escherichia coli-induced inflammatory responses. Granulocyte and monocyte oxidative burst was complement dependent as it was reduced by 85% and 70%, respectively, by the C3 [corrected] binding peptide compstatin. A similar reduction was found by inhibition of C5, C5a, and C5a receptor (C5aR). Furthermore, anti-CR3 antibodies were as efficient as the C5aR antagonist in reducing granulocyte oxidative burst, whereas blocking CD14 or C3aR had no effect. Up-regulation of granulocyte CR3 was virtually abolished by a C5aR antagonist. Opsonization and phagocytosis was completely inhibited by blocking of C5aR or CR3, whereas blocking of the FcgammaRs (CD16, CD32, CD64) had no effect. In contrast to oxidative burst and phagocytosis, cytokine secretion was largely complement independent. Thus, anti-CD14 abolished tumor necrosis factor-alpha, interleukin-6 (IL-6), and IL-10 secretion, whereas IL-8 was equally inhibited by anti-CD14 and compstatin. In conclusion, the present model is particularly useful for studying complement as part of the inflammatory network. The results emphasize a crucial role for C5a-C5aR interaction in E coli-induced up-regulation of CR3 and the subsequent oxidative burst and phagocytosis. Complement inhibition may have therapeutic implications in oxidative burst-induced tissue damage.